--Trial to be used in support of NDA submission-- MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc...
MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present at...
MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has secured a committed...
MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present...
MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has completed a planned...
-- Analysis Shows Potential of LEVADEX to Treat a Broad Spectrum of Migraine -- -- Company to Host Webcast on Monday, September 14th at 7:15 a.m...
- Investor Webcast to Discuss Phase 3 LEVADEX(TM) Data Presented in Late-Breaking Session at the 14th Congress of the International Headache...
AstraZeneca PLC (AZN), a major international healthcare business, said Thursday it has terminated the license agreement with MAP Pharmaceuticals...
- Company to Suspend Development of UDB - MOUNTAIN VIEW, Calif., July 9 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today...
MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that it has priced its initial public offering...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads